Fluticasone furoate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fluticasone furoate
Fluticasone furoate.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
License data
Pregnancy
category
  • C for Intranasal
Routes of
administration
Intranasal
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability0.51% (Intranasal)
Protein binding91%
MetabolismIntranasal
Hepatic (CYP3A4-mediated)
Elimination half-life15 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard100.158.130 Edit this at Wikidata
Chemical and physical data
FormulaC27H29F3O6S
Molar mass538.576 g/mol
3D model (JSmol)

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst and Flonase Sensimist (US), Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, Italy and South Korea) for the treatment of non-allergic and allergic rhinitis administered by a nasal spray.[1]

The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK), is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.[2] As of 2015, it is also approved for the treatment of asthma. [3]

See also[edit]

References[edit]

  1. ^ Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596.
  2. ^ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. May 10, 2013.
  3. ^ "BREO® ELLIPTA® 100/25 (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder)" (PDF).